1. Home
  2. KRKR vs XBIO Comparison

KRKR vs XBIO Comparison

Compare KRKR & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 36Kr Holdings Inc.

KRKR

36Kr Holdings Inc.

HOLD

Current Price

$2.93

Market Cap

5.6M

ML Signal

HOLD

Logo Xenetic Biosciences Inc.

XBIO

Xenetic Biosciences Inc.

N/A

Current Price

$2.30

Market Cap

5.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KRKR
XBIO
Founded
2010
N/A
Country
China
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6M
5.8M
IPO Year
2019
2011

Fundamental Metrics

Financial Performance
Metric
KRKR
XBIO
Price
$2.93
$2.30
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
3.2K
★ 97.5K
Earning Date
03-17-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 38.52
EPS
★ N/A
N/A
Revenue
N/A
★ $2,976,411.00
Revenue This Year
N/A
$2.81
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 19.04
52 Week Low
$2.50
$1.90
52 Week High
$7.57
$13.93

Technical Indicators

Market Signals
Indicator
KRKR
XBIO
Relative Strength Index (RSI) 40.19 35.24
Support Level $2.85 $2.14
Resistance Level $3.30 $2.62
Average True Range (ATR) 0.16 0.32
MACD -0.02 -0.15
Stochastic Oscillator 17.95 7.34

Price Performance

Historical Comparison
KRKR
XBIO

About KRKR 36Kr Holdings Inc.

36KR Holdings Inc is a holding company and conducts its business mainly through its subsidiaries, a VIE, and subsidiaries of the VIE. The Group is engaging in providing content and business services to new economy participants in the PRC. Its content production process includes content creation, content editing, screening and monitoring, and content distribution. The Group mainly generates revenues from providing online advertising services, enterprise value-added services, and subscription services. The Group's principal operations and geographic markets are substantially located in the PRC.

About XBIO Xenetic Biosciences Inc.

Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.

Share on Social Networks: